Table 5 Exposure to study opioids and propofol during the maintenance phase (intent to treat population)
Maintenance phase | Remifentanil (n = 77) | Fentanyl (n = 75) |
|---|---|---|
Median duration of study opioid infusion (hours; range) | 13.7 (2.7–73.0) | 14.2 (0.3–73.3) |
Weighted mean study opioid infusion rate (μg/kg per hour; range) | 9.4 (2.3–22.8) | 1.8 (0.5–6.0) |
Number of patients receiving the study drug infusion for >24 hours | 11 (14%) | 10 (13%) |
Number of patients who received a propofol infusion | 27 (35%) | 30 (40%) |
Mean time from starting the opioid infusion to starting the propofol infusion (hours; range) | 6.6 (0.2–55.6) | 5.9 (0.2–38.6) |
Median duration of propofol infusion (hours; range) | 9.4 (0.6–53.3) | 12.0 (2.5–72.3) |
Mean % of time patients received a propofol infusion (range) during the maintenance phase | 62.8 (3.8–98.9) | 76.1 (26.9–99.0) |
Median total propofol dose (mg; range) | 378.4 (15.8–4690.8) | 683.0 (30.0–11323.3) |
Weighted mean infusion rate of propofol (mg/kg per hour; range) | 0.7 (0.1–2.7) | 0.8 (0.2–2.5) |
Number of patients receiving the following numbers of propofol bolus doses | (n = 27) | (n = 30) |
0 | 18 (67%) | 14 (47%) |
1–3 | 8 (30%) | 11 (37%) |
4–6 | 1 (4%) | 4 (13%) |
≥ 7 | 0 | 1 (3%) |
Number of patients receiving the following numbers of propofol rate increases | (n = 27) | (n = 30) |
0 | 17 (63%) | 6 (20%) |
1–3 | 5 (19%) | 14 (47%) |
4–6 | 3 (11%) | 5 (17%) |
≥ 7 | 2 (7%) | 5 (17%) |
Number (%) of patients receiving the following numbers of propofol rate decreases | (n = 27) | (n = 30) |
0 | 16 (59%) | 18 (60%) |
1–3 | 9 (33%) | 8 (27%) |
4–6 | 2 (7%) | 3 (10%) |
≥ 7 | 0 (0%) | 1 (3%) |